Lupin Ltd. (LUPIN)
XNSE XNSE Primary MSE Summary
LUPIN Chart
People also search for
Lupin Ltd. (LUPIN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lupin Ltd. ever had a stock split?
Lupin Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Ms. Vinita D. Gupta CEO | XNSE Exchange | Y5362X101 CUSIP |
| India Country | 24,006 Employees | 17 Jul 2026 Last Dividend | 27 Aug 2010 Last Split | - IPO Date |
Overview
Lupin Limited is a prominent pharmaceutical entity that embarks on the development, production, marketing, and sale of a comprehensive suite of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs), serving both the domestic Indian market and an international clientele. Initially inaugurated as Lupin Chemicals Limited, the company underwent a rebranding to Lupin Limited in the year 2001, marking a significant milestone in its journey since its foundation in 1968. With its headquarters firmly established in Mumbai, India, Lupin Limited has expanded its operational framework to encompass an extensive network that includes laboratories, LupiMitra collection centers, and an assortment of pick-up points strategically placed to optimize its service outreach. The organization is not only celebrated for its production capabilities but also for its dynamic involvement in bio clinical research activities, prominently focused on pioneering drug discovery and development initiatives across critical therapeutic areas such as oncology, immunology, and metabolic disorders.
Products and Services
- Branded and Generic Formulations
- Biotechnology Products
- Active Pharmaceutical Ingredients (APIs)
- Specialty Products
- Over-the-Counter (OTC) Products
- Drug Discovery and Development
- Bio Clinical Research
Lupin Limited offers a diverse assortment of branded and generic pharmaceutical formulations tailored for various therapeutic areas including cardiovascular, diabetology, asthma, pediatrics, central nervous system (CNS), gastrointestinal, anti-infectives, NSAID therapy, respiratory, women's health, and anti-tuberculosis treatments, catering to a wide spectrum of healthcare needs.
The company's biotechnology sector is distinguished by its production of cutting-edge biotech products, with a significant focus on the development and commercialization of biosimilars. These offerings reflect Lupin Limited's commitment to providing accessible and affordable biopharmaceutical solutions.
Lupin Limited is a key player in the API market, producing and supplying high-quality active pharmaceutical ingredients that serve as the critical backbone for drug manufacturing across the globe, ensuring efficacy and safety in pharmaceutical products.
The enterprise's portfolio is further enriched with specialty products that cater to niche segments and more complex medical conditions, emphasizing Lupin Limited's role in addressing unmet medical needs through innovative pharmaceutical solutions.
In addition to prescription medications, Lupin Limited also offers a range of over-the-counter products, making essential medicines and health products more accessible to the general public and contributing to overall well-being and health management.
Lupin Limited actively engages in drug discovery and development programs, particularly in the fields of oncology, immunology, and metabolic disorders. These research-driven initiatives demonstrate the company's dedication to advancing medical science and introducing novel therapies to the market.
The company's commitment to innovation extends to its bio clinical research activities, where Lupin Limited focuses on the exploration and validation of new treatment possibilities, thereby contributing to the global scientific community and enhancing patient care practices.
